Topics

Human medicines European public assessment report (EPAR): Vosevi, sofosbuvir / velpatasvir / voxilaprevi, Hepatitis C, Chronic, Date of authorisation: 26/07/2017, Revision: 4, Status: Authorised

11:00 EDT 29 Apr 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Vosevi, sofosbuvir / velpatasvir / voxilaprevi, Hepatitis C, Chronic, Date of authorisation: 26/07/2017, Revision: 4, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Vosevi, sofosbuvir / velpatasvir / voxilaprevi, Hepatitis C, Chronic, Date of authorisation: 26/07/2017, Revision: 4, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Vosevi, sofosbuvir / velpatasvir / voxilaprevi, Hepatitis C, Chronic, Date of authorisation: 26/07/2017, Revision: 4, Status: Authorised"

Quick Search

Relevant Topic

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...